AHA/ACC 2025: high blood pressure in adults
International AHA/ACC Current
2025 AHA/ACC/Multisociety Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults
Jones DW, et al. Hypertension. 2025;82:e212–e316
DOI 10.1161/HYP.0000000000000249 · Summary checked against the source: 2026-11
At a glance
- Overall goal: <130/80 for all adults. Make allowances for people in institutional care, with limited life expectancy, or who are pregnant. [e214]
- Categories are unchanged from 2017: normal, elevated, stage 1 (≥130/80) and stage 2 (≥140/90). [e222]
- Risk is now estimated with PREVENT, which replaces the Pooled Cohort Equations. "Increased risk" means a 10-year CVD risk of ≥7.5%. [e243]
- Starting drugs:
- everyone with BP ≥140/90
- at ≥130/80 if they have clinical CVD, diabetes, CKD or PREVENT risk ≥7.5%
- for everyone else, if BP is still ≥130/80 after 3–6 months of lifestyle change [e243–e244]
- Stage 2: start two first-line drugs in a single-pill combination. [e247]
- Screen for primary aldosteronism in every resistant hypertension, even with a normal potassium. [e231]
- Use home BP monitoring with team-based care. Don't use cuffless devices or smartwatches for measurement yet. [e214]
- Severe hypertension (>180/120) without acute organ damage is an outpatient problem. Restart or step up oral drugs. Don't give intermittent IV boluses to inpatients. [e214, e278]
Classification
Adapted from AHA/ACC 2025 Table 4 and Table 7 [e222, e228]. Use the average of ≥2 readings on ≥2 occasions. If systolic and diastolic fall in different categories, use the higher one.
| Category | Office SBP | Office DBP | Home / daytime ABPM | 24-h ABPM | Night ABPM | |
|---|---|---|---|---|---|---|
| Normal | <120 | and | <80 | <120/80 | <115/75 | <100/65 |
| Elevated | 120–129 | and | <80 | – | – | – |
| Stage 1 | 130–139 | or | 80–89 | ≥130/80 | ≥125/75 | ≥110/65 |
| Stage 2 | ≥140 | or | ≥90 | ≥135/85 | ≥130/80 | ≥120/70 |
Diagnosis
Class 1: measure properly
Class 2a: confirm out of the office
- Untreated office BP ≥130/80 but <160/100: confirm with home or ambulatory BP to exclude white-coat hypertension before diagnosing. [2a, B-NR · e229]
- Apparent resistant hypertension: exclude the white-coat effect with out-of-office BP. [2a, C-LD · e229]
- An automated oscillometric device is preferred to auscultation in the office. [2a, C-EO · e224]
Class 2b: look for masked hypertension
Primary aldosteronism: who to screen [e233–e234]
Class 1: screen for primary aldosteronism if any of these
- Resistant hypertension (whatever the potassium)
- Hypokalaemia (spontaneous or diuretic-induced)
- Obstructive sleep apnoea
- Adrenal incidentaloma
- Family history of early-onset hypertension, or stroke before age 40
Screen with plasma aldosterone, renin activity and the aldosterone-to-renin ratio. Keep most antihypertensives going during screening; stop only MRAs. [1, C-LD/C-EO]
Class 2b
Lifestyle [e239]
Class 1, LOE A: for everyone with elevated BP or hypertension
- Weight: lose at least 5% of body weight if overweight.
- Diet: follow a heart-healthy pattern such as DASH.
- Sodium: <2300 mg/day, aiming for <1500 mg/day.
- Potassium: moderate potassium intake, ideally from food (caution in CKD or with drugs that retain potassium).
- Alcohol: abstinence is best; otherwise ≤1 drink/day for women, ≤2 for men.
- Exercise: structured aerobic and/or resistance training.
Class 2a
When to start drugs
flowchart TD
BP["Patient's BP category<br/>lifestyle therapy at every level (Class 1)"] --> N["Normal<br/><120/80"]
BP --> E["Elevated<br/>120–129 / <80"]
BP --> S1["Stage 1<br/>130–139 / 80–89"]
BP --> S2["Stage 2<br/>≥140/90"]
N --> N1["Reassess in 1 year"]
E --> E1["Reassess in 3–6 months"]
S1 --> Q{"Clinical CVD, diabetes, CKD<br/>or PREVENT 10-yr CVD risk ≥7.5%?"}
Q -- No --> R["Reassess in 3–6 months"]
R --> Q2{"Still stage 1<br/>130–139 / 80–89?"}
Q2 -- No --> R
Q2 -- Yes --> M
Q -- Yes --> M["BP-lowering medication<br/>AND reassess in 1 month"]
S2 --> M
M --> G{"BP goal met?"}
G -- No --> I["Intensify therapy<br/>while optimising adherence"]
I --> M
G -- Yes --> F["Reassess in 3–6 months"]
F --> G
Adapted from AHA/ACC 2025 Figure 7 [e270]; risk questions from Figure 6 [e245]. Every box in the original is Class 1.
Class 1: thresholds
- All adults: start drugs at average SBP ≥140 or DBP ≥90. [1, A · e243]
- Clinical CVD (CHD, stroke, HF): start at ≥130/80. [1, A / C-LD · e243]
- No CVD, but diabetes, CKD or PREVENT ≥7.5%: start at ≥130/80. [1, A / C-LD · e244]
- No CVD, PREVENT <7.5%: start if still ≥130/80 after a 3–6 month lifestyle trial. [1, B-R · e244]
- Follow-up: after starting or changing drugs, review monthly until BP is controlled. [1, B-R · e267]
Which drugs [e247]
Class 1: first-line drugs and starting regimen
Class 2a
Targets [e252]
Class 1: increased CVD risk (PREVENT ≥7.5%, CVD, diabetes or CKD)
Class 2b: not at increased risk
Special groups
Class 1 [e215]
- With eGFR <60 and albuminuria ≥30 mg/g, use a RAAS inhibitor (ACEi or ARB, never both) to cut CVD risk and slow CKD.
Acute ICH [e263]
Acute ischaemic stroke: thrombolysis [e263]
Acute ischaemic stroke: no reperfusion
Acute ischaemic stroke: no benefit or harm [e264]
- BP <220/120 with no reperfusion treatment: starting or restarting antihypertensives in the first 48–72 h doesn't help. [3: No benefit, A]
- After successful thrombectomy, lowering SBP to <140 in the first 24–72 h worsens outcome. [3: Harm, A]
Class 1 [e269]
Class 2b
Resistant hypertension [e274]
flowchart TD
A["Step 1: Confirm treatment resistance (either):<br/>office BP ≥130/80 on ≥3 drugs, or<br/>office BP <130/80 but needs ≥4 drugs<br/>(ACEi or ARB + CCB + thiazide-like preferred)"] --> B["Step 2: Exclude pseudoresistance<br/>accurate office BP · check adherence<br/>home, work or ambulatory BP for white-coat effect"]
B --> C["Step 3: Identify and reverse contributing lifestyle factors"]
C --> D["Step 4: Stop or minimise interfering substances<br/>(Table 11)"]
D --> E["Step 5: Screen for secondary causes"]
E --> F["Step 6: Drug treatment (next box)"]
F --> G["Step 7: Refer to a specialist<br/>known or suspected secondary cause, or<br/>BP still uncontrolled after 6 months of treatment"]
Adapted from AHA/ACC 2025 Figure 8 [e276]
Step 6: drug treatment in Figure 8
- Maximise the diuretic: replace a thiazide-type diuretic with chlorthalidone 12.5–25 mg once daily or indapamide 1.25–2.5 mg once daily.
- Add spironolactone 25–50 mg once daily (or eplerenone 25–50 mg twice daily) if eGFR ≥45. [1, B-R · e274]
- CKD stage 4 or worse: use chlorthalidone or a loop diuretic.
- Add a drug with a different mechanism: beta-blocker, central sympatholytic, or non-dihydropyridine CCB if the heart rate is high.
- Then: a dual endothelin-receptor antagonist (for example aprocitentan) or a potent vasodilator. Use hydralazine or minoxidil only if the patient is already on a beta-blocker (or bradycardic) and a loop diuretic.
Class 2a: if an MRA can't be used
Renal denervation
Hypertensive emergency [e278]
flowchart TD
A["SBP >180 or DBP >120"] --> B{"Acute target organ damage?*"}
B -- Yes --> E["Hypertensive emergency<br/>admit to ICU (Class 1)"]
E --> C{"Aortic dissection or<br/>phaeochromocytoma crisis?"}
C -- "Aortic dissection" --> AD["Reduce SBP to <120<br/>(Class 1)"]
C -- "Phaeochromocytoma crisis" --> PH["Reduce SBP to <140<br/>in the first hour (Class 1)"]
C -- No --> N["Reduce SBP by 25% in the first hour,<br/>to <160/100–110 over the next 6 h,<br/>then to normal over the next 24–48 h (Class 1)"]
B -- No --> S["Severe hypertension"]
S --> ED["Found in the emergency department:<br/>decide inpatient vs outpatient care<br/>on indications other than BP"]
S --> OP["Found in outpatients:<br/>no need to send to the ED<br/>restart, intensify or modify oral therapy"]
ED --> AV["AVOID parenteral BP lowering or<br/>intensified oral therapy in the acute setting<br/>(Class 3: Harm)"]
ED --> FU["Close outpatient follow-up<br/>within 4 weeks"]
OP --> FU
Adapted from AHA/ACC 2025 Figure 9 [e283]. *Acute target organ damage: acute HF or pulmonary oedema, neurological emergencies (PRES, encephalopathy, retinal haemorrhage, papilloedema, ICH, acute ischaemic stroke), acute coronary syndrome, acute kidney injury, acute aortic syndrome.
Figure vs recommendation text
The written recommendation is slightly different from Figure 9 in the non-compelling pathway: no more than 25% in the first hour, then <160/100 over the next 2–6 h, then 130–140 over the next 24–48 h. It also covers "other compelling conditions" beyond dissection, with SBP <140 in the first hour. [1, C-LD · e278]
Class 3: harm
What's new since 2017 [Table 1 · e215–e216]
- PREVENT (≥7.5%) replaces the PCE (≥10% ASCVD) as the risk threshold.
- Screening for primary aldosteronism is extended to all resistant hypertension, without needing to stop most drugs first.
- Potassium-based salt substitutes are now recommended (2a).
- In diabetes, ACEi/ARB moved from 2b to Class 1 when there's CKD or albuminuria.
- New: SBP <130 is recommended to prevent mild cognitive impairment and dementia (Class 1).
- New pregnancy recommendations: aspirin; treat ≥160/110 within 30–60 min; chronic hypertension target <140/90.
- New renal denervation recommendations.
- "Hypertensive urgency" is renamed severe hypertension.
Clinical pearls
- Stage 1 starts at 130/80. Stage 2 starts at 140/90.
- PREVENT is validated for ages 30–79.
- The threshold for starting drugs in someone without CVD, diabetes or CKD who has low PREVENT risk is still effectively 140/90, or ≥130/80 after 3–6 months of lifestyle change.
- Home BP of 135/85 corresponds to office 140/90. Home BP of 130/80 corresponds to office 130/80.
- Out-of-office BP is only needed to confirm untreated readings below 160/100.
Classes and levels of evidence
How AHA/ACC 2025 grades its recommendations. Adapted from AHA/ACC 2025 Table 3 (updated December 2024) [e221]. Hover over any class or level cited on this page to see what it means.
| Class | Strength | Meaning | Wording used |
|---|---|---|---|
| Class 1 | Strong | Benefit >>> risk | is recommended; is indicated, useful, effective or beneficial; should be performed or administered |
| Class 2a | Moderate | Benefit >> risk | is reasonable; can be useful, effective or beneficial |
| Class 2b | Weak | Benefit ≥ risk | may or might be reasonable; may or might be considered; usefulness is unknown, unclear or uncertain |
| Class 3: No benefit | Moderate | Benefit = risk (generally used only with level A or B) | is not recommended; is not indicated, useful or effective; should not be performed or administered |
| Class 3: Harm | Strong | Risk > benefit | potentially harmful; causes harm; associated with excess morbidity or mortality; should not be performed or administered |
| Level | Meaning |
|---|---|
| Level A | High-quality evidence from more than one RCT, meta-analyses of high-quality RCTs, or one or more RCTs corroborated by high-quality registry studies |
| Level B-R (randomised) | Moderate-quality evidence from one or more RCTs, or meta-analyses of moderate-quality RCTs |
| Level B-NR (non-randomised) | Moderate-quality evidence from one or more well-designed, well-executed non-randomised, observational or registry studies, or meta-analyses of such studies |
| Level C-LD (limited data) | Randomised or non-randomised observational or registry studies with limitations of design or execution, meta-analyses of such studies, or physiological or mechanistic studies in humans |
| Level C-EO (expert opinion) | Consensus of expert opinion based on clinical experience |
Class (strength) and level (quality) are judged independently, so any class can pair with any level. A level C recommendation isn't necessarily weak: many important clinical questions can't be tested in trials, yet there may be clear clinical consensus.